RIGL: VEPPANU launch and robust pipeline drive growth, with strong financials and raised guidance
A four-part growth strategy is driving expansion, highlighted by the VEPPANU acquisition and launch, which targets a billion-dollar breast cancer market. The pipeline, led by R289 in MDS, shows promising clinical results, while financials remain strong with raised revenue guidance.Based on Rigel Ph…
A four-part growth strategy is driving expansion, highlighted by the VEPPANU acquisition and launch, which targets a billion-dollar breast cancer market. Based on Rigel Ph…